Home ›
Entities
› academia
› Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).
Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).
Research article (Journal of Clinical Oncology, 2022) · cited 16× · AI/ML
Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).
Summary
Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J). is a scholarly article[1].
Key Facts
Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).'s instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).. Retrieved May 24, 2026, from https://4ort.xyz/entity/ulixertinib-in-patients-with-tumors-with-mapk-pathway-alterations-results-from-nci-cog-pediatric-match-trial-arm-j-apec1
MLA“Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J)..” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/ulixertinib-in-patients-with-tumors-with-mapk-pathway-alterations-results-from-nci-cog-pediatric-match-trial-arm-j-apec1.
BibTeX@misc{4ortxyz_ulixertinib-in-patients-with-tumors-with-mapk-pathway-alterations-results-from-nci-cog-pediatric-match-trial-arm-j-apec1_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).}}, year = {2026}, url = {https://4ort.xyz/entity/ulixertinib-in-patients-with-tumors-with-mapk-pathway-alterations-results-from-nci-cog-pediatric-match-trial-arm-j-apec1}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J). — https://4ort.xyz/entity/ulixertinib-in-patients-with-tumors-with-mapk-pathway-alterations-results-from-nci-cog-pediatric-match-trial-arm-j-apec1 (retrieved 2026-05-24)
